Bris­tol-My­ers set to get a boost in Chi­na as Op­di­vo aces PhI­II lung can­cer study ear­ly

Bris­tol-My­ers Squibb ap­pears poised to win a big niche in Chi­na’s can­cer drug mar­ket. The com­pa­ny re­port­ed Thurs­day night that their Phase III com­par­ing their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.